 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
3 News |  |
- ONCT-808 / Oncternal Therap
Trial-in-Progress: A Phase 1/2 Multi-Center Study of Onct-808, a ROR1-Specific CAR T, in Adult Patients with Relapsed/Refractory Aggressive B Cell Lymphoma (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6314;
P1/2
Zilovertamab vedotin showed preliminary evidence of efficacy and no evidence of on-target off-tumor toxicity in patients with advanced B cell malignancies (Wang 2022)...Subjects will receive a conditioning regimen of intravenous (IV) cyclophosphamide and fludarabine, followed by ONCT-808 IV infusion...The trial is currently active and patients have been treated in the phase 1 dose escalation. Clinical Trial Identifier: NCT05588440
- ONCT-808 / Oncternal Therap
Development of a high yield, fully automated ONCT-808 autologous ROR1 CAR T cell clinical manufacturing process (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_787;
Clinical Trial Identifier: NCT05588440 ONCT-808 cells are genetically modified via ex vivo transduction with lentivirus vector to express a CAR construct containing a ROR1-directed single chain variable fragment (scFv) derived from Oncternal
- ONCT-808 / Oncternal Therap
ONCT-808 ROR1 CAR T cells induce significant cancer cell death in mantle cell lymphoma cell line-derived CDX models and in vitro killing assays (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_597;
ONCT-808 cells are genetically modified via ex vivo transduction with lentivirus vector to express a CAR construct containing a ROR1-directed single chain variable fragment (scFv) derived from Oncternal Oncternal
- ||| ONCT-808 / Oncternal Therap
Enrollment open, Trial initiation date: A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - Jun 15, 2023
P1/2, N=57, Recruiting, Sponsor: Oncternal Therapeutics, Inc
Oncternal Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> May 2023
- |||| ONCT-808 / Oncternal Therap
New P1/2 trial: A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - Oct 20, 2022
P1/2, N=57, Not yet recruiting, Sponsor: Oncternal Therapeutics, Inc
- TK216 / Oncternal Therapeutics, cirmtuzumab (UC-961) / Oncternal Therapeutics, ROR1 CAR T-cell therapy / Oncternal Therapeutics
[VIRTUAL] Oncternal Therapeutics () - Jun 9, 2020 - Abstract #BIO2020BIO_405;
Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The pipeline includes cirmtuzumab (ROR1 antibody in Phase 1/2), TK216 (targeted ETS inhibitor in Phase 1) and ROR1 CAR-T cell therapy (in preclinical).
- cirmtuzumab (UC-961) / Oncternal Therapeutics, ROR1 CAR T-cell therapy / Oncternal Therapeutics
Preclinical evaluation of anti-ROR1 CAR T cells employing a ROR1 binding SCFV derived from the clinical stage mab cirmtuzumab. (Gatlin Ballroom B, Level 1 - Poster Board D5) - Dec 17, 2019 - Abstract #ASCOSITC2020ASCO_SITC_245;
As ROR1 expression and signaling has been associated with cancer stemness and chemo-resistance utilizing ROR1 CAR-T therapy to target cancer cells might mitigate tumor escape. These data strongly support the rationale for continued development of our ROR1 CAR-T.
- cirmtuzumab (UC-961) / Oncternal Therapeutics, ROR1 CAR T-cell therapy / Oncternal Therapeutics
Preclinical evaluation of anti-ROR1 CAR T cells employing a ROR1 binding SCFV derived from the clinical stage mab cirmtuzumab. (Gatlin Ballroom B, Level 1 - Poster Board D5) - Dec 17, 2019 - Abstract #ASCOSITC2020ASCO_SITC_154;
As ROR1 expression and signaling has been associated with cancer stemness and chemo-resistance utilizing ROR1 CAR-T therapy to target cancer cells might mitigate tumor escape. These data strongly support the rationale for continued development of our ROR1 CAR-T.